The Top 5 Biosimilar Articles for the Week of June 7

Here are the top 5 biosimilar articles for the week of June 7, 2021.

Hi, I’m Skylar Jeremias for The Center for Biosimilars®, your resource for clinical, regulatory, business, and policy news in the rapidly changing world of biosimilars.

Here are the top 5 biosimilar articles for the week of June 7, 2021.

Number 5: Bio-Thera Solutions initiated a phase 3 clinical study for its golimumab biosimilar candidate (BAT2506) referencing Simponi.

Number 4: Organon said that it will do marketing but not research and development, Biogen and Bio-Thera moved forward with a tocilizumab candidate, and Lupin promoted a pegfilgrastim biosimilar.

Number 3: Investigators further elucidated the equivalence of a trastuzumab biosimilar vs Herceptin in HER2+ (human epidermal growth factor receptor 2–positive) breast cancer.

Number 2: When biosimilars emerged in oncology, oncologists dipped in a toe and then got serious, according to a retrospective study on usage and savings presented at ASCO 2021.

Number 1: Sarfaraz K. Niazi, PhD, a member of The Center for Biosimilars® Advisory Board, reported on his citizen petition to the FDA to rationalize testing of biosimilars.

To read all of these articles and more, visit centerforbiosimilars.com.

Related Videos
Here are the top 5 biosimilar articles for the week of May 22, 2023.
Fran Gregory, PharmD, vice president of emerging therapies at Cardinal Health
Here are the top 5 biosimilar articles for the week of May 15th, 2023.
Here are the top 5 biosimilar articles for the week of May 8, 2023.
andre harvin
Here are the top 5 biosimilar articles for the week of May 1, 2023.
Here are the top 5 biosimilar articles for the week of April 24, 2023.
Andre Harvin, PharmD
Here are the top 5 biosimilar articles for the week of April 17, 2023.
Here are the top 5 biosimilar articles for the week of April 10, 2023.
Related Content
© 2023 MJH Life Sciences

All rights reserved.